Introduction: α-synuclein aggregates have been identified in the retina of Parkinson's disease patients associated to vision impairment. In this study, we sought to determine the effects of αsynuclein overexpression on the survival and function of dopaminergic (DA) amacrine cells in the retina.
INTRODUCTION
The two hallmarks of Parkinson's disease (PD) are the formation of α-synuclein (α-syn) inclusions into Lewy bodies (LBs) 1 and the degeneration of the nigrostriatal dopaminergic systems leading to motor and cognitive deficits in PD. Experimental evidence in animal models established a causal link between α-syn overexpression or mutations and the degeneration of dopaminergic neurons, by showing that recombinant adeno-associated viral vector (rAAV)mediated overexpression of human wild-type (WT) α-syn in the midbrain of adult rodents leads to progressive loss of nigral dopaminergic neurons 2, 3 . Starting from the clinical observation that PD patients also present with visual symptoms such as reduced visual acuity, low contrast sensitivity, altered electroretinogram (ERG) and disturbed color vision [4] [5] [6] [7] , recent findings are considering the retina as a potential biomarker for PD. α-syn aggregates have been identified in the retina of PD patients and in particular in the Ganglion Cell Layer (GCL), Inner Plexiform Layer (IPL) and Inner Nuclear Layer (INL) 8 .
According to clinical studies, transgenic mouse models overexpressing α-syn reported an accumulation of the protein in specific retinal cells depending on the promoter used for the expression 9 . A transgenic mouse model overexpressing a fused α-syn-GFP under the Platelet Derived Endothelial Growth Factor (PDGFβ) promoter reported dot-like deposits in the INL and in the retinal ganglion cells (RGC) increasing over time 10 , and leading to their degeneration. However, none of these studies explored the effects of synucleinopathy on dopaminergic (DA) amacrine cells of the retina, which are located in the INL [11] [12] [13] .
In the retina, DA neurotransmission is regulated by a single subpopulation of amacrine cells (A18 cells) 14 that synthesizes and releases DA neurotransmitter 15, 16 . DA plays a crucial role in the modulation of light adaptation. Light stimuli, through rods, cones, and melanopsin ganglion cells activate dopaminergic amacrine cells, triggering dopamine release 17, 18 . Extracellular DA acts on dopaminergic receptors. In particular, D1-like receptors are expressed not only by amacrine cells but also in horizontal cells and bipolar cells; rods and cone mainly express D4R;
D4R stimulation reduces the rod-cone communication through the gap junctions, which increases the direct response of cones in photopic conditions [14] [15] [16] . On the contrary, the absence of DA favors the rod-cone conductance and the shunting cone electrical signal. Retinal dopaminergic tone is thought to amplify the cone circuits flow, producing a shift from rod-dominant to conedominant vision during daylight [19] [20] [21] . DA cells also contribute to color vision. These visual functions are frequently compromised in Parkinsonian patients 15, 22 .
In this study we show, for the first time, that α-syn overexpression in the retina leads to neurodegeneration of DA amacrine cells, causing retinal-specific defects and a consequent visual function impairment.
MATERIAL AND METHODS

Subjects
All the experiments were performed in male and female inbred C57BL/6J adult (12-20 weeks old) mice. Group housed mice, with ad libitum access to water and food, were maintained at 22±1 °C and 55±5% relative humidity, with a 12-h light: 12-h dark cycle (lights on 07:30-19:30) and tested during the light phase. The experiments were conducted in accordance with the European Communities Council directives and Italian laws on animal care.
Intravitreal injections
Animals were intravitreally injected with the same recombinant adeno-associated viral vector (rAAV) 2/6 expressing human (hu) α-synuclein (rAAV2/6-hu-α-syn) or with a rAAV2/6 expressing GFP (rAAV2/6-GFP) (7.7 x 10 13 genome copies/ml) previously described 2 .
Intravitreal injection of rAAV2/6 has been previously reported to transduce the retina in mice and rats 23, 24 . Pupils of anaesthetized animals (100 mg/kg medetomidine and 0.25 mg/kg ketamine) were dilated using 1% tropicamide and 2.5% phenylephrine (Chauvin, Essex, UK) and a small guide hole was made under the limbus with a 30G needle. The eye was gently massaged with a cotton swab to remove a portion of the vitreous to avoid a post-injection reflux of vitreous and/or drug solution. Then, 1 µL of vector was intravitreal injected through the initial hole using a 34G Hamilton syringe.
Visual acuity test
We used a behavioral procedure of the visual acuity task modified from Prusky's 25 and Robison's 26 procedures and described in supplementary materials.
Electrophysiological recordings:
Mice were anesthetized and accommodated in a stereotaxic apparatus; their pupils were dilated with 1% tropicamide and 2.5% phenylephrine (Chauvin, Essex, UK). 
Dark-adapted ERG:
Drugs
Benserazide (20 mg/kg, Sigma Aldrich) in PBS 1x was injected intraperitoneally (i.p.) injected 15 minutes before L-DOPA (10 mg/kg, Sigma Aldrich, in saline solution, i.p.) or saline. Each animal received L-DOPA and saline 5-7 days apart in randomized order.
Immunofluorescence
One, two or three months after rAAV-injection, the eyes were removed and fixed in 4% paraformaldehyde fixative solution (PFA), cryoprotected in PBS sucrose, embedded in OCT (Optimal cutting temperature) and cut by cryostat at 12 μm. Sections were processed by immunofluorescence as previously described 2 , using the following primary antibodies: TH (AB 
Results
α-synuclein overexpression in the retina leads to vision impairment, which is rescued by L-
DOPA administration.
α-syn was expressed in the retina of adult C57BL/6J mice, through an intravitreal bilateral injection of rAAV-hu-α-syn (experimental cohort) or rAAV-GFP (control cohort). We used a within subject experimental design, by testing the animal abilities to adapt to light changes under rod saturating conditions with ERG and assess their visual acuity in the water maze task, before and after rAAV injection ( Fig. 1A) . To mimic the adaptation to light, a series of flashes at a In order to evaluate whether α-syn overexpression in the retina leads to changes in visual acuity, we investigated the ability of α-syn injected mice to discriminate between two different spatial frequencies in the water maze task using behavioral procedures similar to those previously published ( Fig. 1E , see Materials and Methods) 28 . Untreated C57BL/6J mice showed maximal visual acuity of about 1.3 c/d (Supplementary Video 1A). rAAV-hu-α-syn injection significantly impaired visual acuity (0.130 c/d) compared to both the pre-injected and rAAV-GFP injected mice ( Fig. 1F, Supplementary Video 1B) . A major advantage of this intravitreal selective expression of α-syn is that it allows to specifically relate the behavioral defects in the water maze with vision impairment, ruling out the role of motor impairments characterizing genetic animal models of synucleinopathy. Systemic administration of L-DOPA rescued the visual acuity defect to pre-treatment condition ( Fig. 1H) (Supplementary Video 1C) . The ameliorative effects of L-DOPA were specific to rAAV-hu-α-syn injected eyes, as L-DOPA did not affect rAAV-GFP injected mice and CD-1 outbred albino mice (Supplementary results and Fig. 1A-B) . Fig. 2A-D) .
α-synuclein overexpression leads to a time-dependent dopamine neuronal loss.
To determine whether the underlying mechanisms of the functional findings correspond to specific histopathological effects we analyzed by immunofluorescence the rAAV injected retinas. At one-month post intravitreal administration, rAAV2/6-GFP transduced efficiently the inner retina including IPL, the deepest INL and extensively the GCL ( Fig. 2A) . In addition, rAAV-hu-α-syn injected retinas showed also positive to phosphorylated α-syn, at serine 129, a specific biomarker of α-syn aggregates and/or misfolded protein 8, 29 . Accordingly, to the functional data, we found a highly significant and progressive (1, 2 and 3 months) reduction of the number of TH-immunoreactive amacrine cells in the retinas, evaluated with both vertical and whole mount slices, of rAAV-hu-α-syn injected mice ( Fig. 2B-C) . Notably, we found an unchanged number of GABAergic glutamic acid decarboxylase 65 (GAD65)-positive amacrine cells and cholinergic amacrine cells expressing Choline acetyltransferase (ChAT) at this early stage ( Supplementary Fig. 3C-D) . Ganglion cell numbers was not affected at one month after the injection, as evaluated through NeuN staining. However, a significant reduction of NeuN+ cells number, was detectable at a later time point (3 months), albeit not to the same extent as that observed in DA amacrine cells ( Fig. 2D-E) . As NeuN in the ganglion cells layer marks both ganglion cells and displaced amacrine cells, we performed RBPMS staining that is selectively expressed in adult ganglion cells, to confirm a degeneration of this neuronal population at this later stage (3 months) ( Fig. 2F-G) .
Discussion
The observation in Parkinsonian patients of a reduced DA innervation in the central retina associated with altered adaptation to light contrast and specific defects in visual acuity was made already 30 years ago 30 . Experimental evidence also provided in genetic and pharmacological animal models, in which loss of function of TH+ amacrine cells results in visual defect that can be corrected by L-DOPA replacement therapy 20,31-33 . More recent evidence suggested that α-syn aggregates, are present in the eye of PD patients, as also confirmed by transgenic animal models of α-synucleinopathy 9,10 , and that phosphorylated α-syn accumulates in the retina in parallel with that in the brain, including in early stages preceding development of clinical signs of parkinsonism or dementia 34 . However, synucleinopathy in the retina has never been directly associated to DA cells neurodegeneration and consequent with visual defects.
In this study, we report for the first time that α-syn overexpression in the retina induces a timedependent loss of TH+ amacrine cells which precedes ganglion cell degeneration. In this model, no detectable changes in the number of GABAergic and cholinergic amacrine cells were observed. Many of the TH+ positive cells co-express GABA; however, TH+ are only a minor part of GABAergic amacrine cells in the INL. Therefore the lack of significant changes in the number of GABA positive amacrine cells might be explained by considering that DA and GABAergic are only a minimal part of the latter, respectively [11] [12] [13] .
The loss of TH+ cells was associated to altered light-adaptation and impaired performance in the visual acuity version of the water maze task.
Although, the histological, electrophysiological and behavioral findings we provide in this study consistently suggest that the impairment in the early stage was selectively induced by DA amacrine cells function, we cannot completely exclude that other neuronal population might be affected at this early stage. Nevertheless, the fact that systemic injection of L-DOPA, which selectively acts on DA neurons, completely rescued the visual defects strongly suggests that the early functional impairments induced by α-syn overexpression are selectively dependent on impaired DA cellular function. These findings show that α-syn exerts harmful effects on DA neurons independently from the cellular context in which they are integrated, including the retina.
The eye is gaining momentum for studying neurodegenerative disorders due to its easy accessibility 35 . Interestingly, we could detect phosphorylated α-syn at this early stage in the retina, which has been suggested as a valid early marker of the pathology 34 . Indeed, it is being considered as an ideal model organ for both an early identification of protein aggregates and for testing novel therapeutic approaches in neurodegenerative disorders.
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Supplementary materials and methods
Visual acuity test
Apparatus: Animals were tested in a circular tank (150 cm diameter, 35.5 cm high) filled with water (22±1 °C). A rectangular white platform (37 cm long x 13 cm wide x 14 cm high) was submerged 1 cm below the water surface and a steel divider (70 cm long) extending toward the center of the pool, divided it in two equal quadrants; the divider constituted the response choice point. Two cards (40×44.5 cm) with vertical pattern black and white stripes of different width were fixed to the wall of the pool in each quadrant. The escape platform was located in front of the card with smaller stripes. Animals discriminated between a card with larger stripes and a card with smaller stripes where the escape platform was located. Correct responses were recorded as direct entry in the quadrant where the card with smaller stripes was located. Visual acuity was finally measured in cycles/degree (c/d) according to the method described in 28 .
Procedure:
The task consisted of three phases: 1. During the shaping phase (day1), animals were habituated to the task, by positioning the card with 10 cm black and white stripes and the platform in the same quadrant so they learned that a platform was associated to a card. The platform and the card were alternatively positioned in left or right quadrant for 3 sessions of 6 trials. Animals were released in the pool at progressively greater distance from the choice point in each session. 2. Training phase: the 10 cm black and white striped card and the 1 cm black and white striped card were randomly positioned in left or right quadrant and the platform was always located under the smaller striped card. Animals were trained to discriminate between two cards and to learn that the platform was always associated to smaller striped card. They were tested for a maximum of 3 sessions per day (10 trials/session, 60 seconds/trial). If the animal made 70% correct responses (criterion) in a session or 4 consecutive correct responses, it was tested in the next phase; if the animals did not reach the criterion, they were re-tested in the training phase for a maximum of 3 days (3 sessions per day) 3. Test phase: couples of cards used were progressively more difficult to discriminate: 10 cm striped card vs. 1 cm striped card, 10 cm striped card vs. 2 cm striped card, 5 cm striped card vs 2 cm striped card, 4 cm striped card vs 3 cm striped card. To go to the next couple of cards mice were required to make 70% corrects responses or 4 consecutive correct responses at the previous couple of cards. Animals were tested for a maximum of 3 sessions per day (10 trials/session, 60 seconds/trial).
6-hydroxidopamine experiment.
A group of mice was intravitreally injected with 6-OHDA (2µg/µL, Sigma Aldrich, 1µL/side) and a group was injected with saline as control. Intravitreal injections were performed as described for viral vector injection (see Materials and Methods). 15-20 days after the injection procedure, mice underwent the behavioral procedure. Systemic L-DOPA or vehicle treatment started 1 week after the injection. The protocol used was the same described for the rAAV injected mice. Each animal was first administered with L-DOPA (n=7) or Vehicle (n=5), one
week apart with the inverse treatment ( Supplementary Fig. 2A-B) .
Male and female outbred CD-1 mice (12-20 weeks old) (n=10) were also used to validate our behavioral procedure. 6 of them were treated with L-DOPA and 4 of them were treated with vehicle.
Statistical analysis
Statistical analysis was performed using a two-way ANOVA for repeated measures for the behavioral analysis before the L-DOPA treatment (between variable: Control and 6-OHDA;
repeated measures: pre and post-lesion) and a three-way ANOVA for repeated measures for the behavioral analysis under L-DOPA treatment (between variables, Group: Control or 6-OHDA, treatment: L-DOPA and Vehicle; repeated measures: pre and post-treatment). TH+ Cells counting was analysed with a one-way ANOVA. Behavioral experiments in CD1 mice were analysed with a one-way ANOVA (between variable: CD-1 and C57BL/6J) or with a two-way ANOVA for the experiment with the L-DOPA treatment. Duncan post-hoc test was used when appropriate and the statistical significance was set at p < 0.05.
Supplementary Results
6-OHDA injection caused similar visual acuity defects to those observed in rAAV-hu-α-syn
injected mice, rescued by L-DOPA treatment.
Intravitreal injection of 6-OHDA in adult mice caused a 50% reduction of TH+ amacrine cells 1 month post-injection ( Supplementary Fig. 2A-B ). 15 days after the injection, 6-OHDA injected mice showed a significant impairment in the visual acuity task so that they did not overcome the first step of the task (10 cm vs 1 cm, 0.313 c/d) ( Supplementary Fig 1C) . L-DOPA treatment completely rescued the defect ( Supplementary Fig. 1D ).
L-DOPA treatment did not rescue visual acuity defect in CD-1 mice.
To further assess the specificity of the effects of L-DOPA on DA, we tested CD-1 albino outbred mice, which have normal levels of DA and L-DOPA, but reduced melanin due to the lack of tyrosinase action on the melanin biosynthetic pathway 36,37 . As expected, albino mice showed
